{"analyses":[{"ciLowerLimit":"0.97","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.41","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0921","paramType":"Odds Ratio (OR)","paramValue":"1.17","statisticalMethod":"Proportional Odds Model"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"34.2","upperLimit":"41.2","value":"37.7"},{"groupId":"OG001","lowerLimit":"36.9","upperLimit":"44.0","value":"40.4"}]}],"title":"Day 10 NIAID-OS 1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"7.3","upperLimit":"11.5","value":"9.4"},{"groupId":"OG001","lowerLimit":"8.7","upperLimit":"13.2","value":"10.9"}]}],"title":"Day 10 NIAID-OS 2"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.0","upperLimit":"0.4","value":"0.1"},{"groupId":"OG001","lowerLimit":"0.0","upperLimit":"0.4","value":"0.1"}]}],"title":"Day 10 NIAID-OS 3"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"13.6","upperLimit":"18.9","value":"16.2"},{"groupId":"OG001","lowerLimit":"11.6","upperLimit":"16.6","value":"14.1"}]}],"title":"Day 10 NIAID-OS 4"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"10.3","upperLimit":"15.2","value":"12.8"},{"groupId":"OG001","lowerLimit":"10.0","upperLimit":"14.8","value":"12.4"}]}],"title":"Day 10 NIAID-OS 5"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"6.1","upperLimit":"10.0","value":"8.1"},{"groupId":"OG001","lowerLimit":"6.8","upperLimit":"11.0","value":"8.9"}]}],"title":"Day 10 NIAID-OS 6"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"8.4","upperLimit":"12.9","value":"10.6"},{"groupId":"OG001","lowerLimit":"8.2","upperLimit":"12.6","value":"10.4"}]}],"title":"Day 10 NIAID-OS 7"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.5","upperLimit":"6.7","value":"5.1"},{"groupId":"OG001","lowerLimit":"1.5","upperLimit":"3.8","value":"2.6"}]}],"title":"Day 10 NIAID-OS 8"}],"denoms":[{"counts":[{"groupId":"OG000","value":"756"},{"groupId":"OG001","value":"762"}],"units":"Participants"}],"description":"Overall improvement on the National Institute of Allergy and Infectious Diseases ordinal scale:\n\n1\\. Not hospitalized, no limitations on activities; 2. Not hospitalized, limitation on activities and/or requiring home oxygen; 3. Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care: (This would include those kept in hospital for quarantine/infection control, awaiting bed in rehabilitation facility or homecare, etc.); 4. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 5. Hospitalized, requiring supplemental oxygen; 6.Hospitalized, on noninvasive ventilation or high-flow oxygen devices; 7. Hospitalized, on invasive mechanical ventilation or ECMO; 8. Death.","dispersionType":"95% Confidence Interval","groups":[{"description":"Placebo administered orally QD with standard of care.","id":"OG000","title":"Placebo + SOC"},{"description":"4 mg baricitinib administered orally QD with standard of care.","id":"OG001","title":"Baricitinib + SOC"}],"paramType":"NUMBER","populationDescription":"All participants randomly assigned to study intervention. Participants with missing baseline ordinal scale were excluded.","reportingStatus":"POSTED","timeFrame":"Day 10","title":"Percentage of Participants at Each Clinical Status Using the National Institute of Allergy and Infectious Diseases Ordinal Scale (NIAID-OS) at Day 10","type":"SECONDARY","unitOfMeasure":"percentage of participants"}